{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T23:46:16Z","timestamp":1768434376717,"version":"3.49.0"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Austrian Forum against Cancer"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,10]]},"abstract":"<jats:p>This\u00a0commentary focuses on data in favor of early treatment initiation or a cautious wait-and-see strategy in smoldering multiple myeloma.<\/jats:p>","DOI":"10.1093\/oncolo\/oyae266","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T17:10:31Z","timestamp":1728407431000},"source":"Crossref","is-referenced-by-count":2,"title":["Controversies in smoldering multiple myeloma: finding the optimal approach for treatment initiation"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3302-8726","authenticated-orcid":false,"given":"Heinz","family":"Ludwig","sequence":"first","affiliation":[{"name":"Wilhelminen Cancer Research Institute, Department of Medicine I, Center for Oncology, Hematology with Outpatient Department, and Palliative Care, Clinic Ottakring , 1160 Vienna ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Schreder","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Center for Oncology, Hematology with Outpatient Department, and Palliative Care, Clinic Ottakring , 1160 Vienna ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"key":"2025033007272234900_CIT0001","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198006123022405","article-title":"Smoldering multiple myeloma","volume":"302","author":"Kyle","year":"1980","journal-title":"N Engl J Med."},{"key":"2025033007272234900_CIT0002","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"2025033007272234900_CIT0003","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med."},{"key":"2025033007272234900_CIT0004","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1300439","article-title":"Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma","volume":"369","author":"Mateos","year":"2013","journal-title":"N Engl J Med."},{"key":"2025033007272234900_CIT0005","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J Clin Oncol."},{"key":"2025033007272234900_CIT0006","first-page":"JCO2302771","article-title":"Curative strategy for high-risk smoldering myeloma: carfilzomib, lenalidomide, and dexamethasone (KRd) followed by transplant, KRd consolidation, and Rd maintenance","author":"Mateos","year":"2024","journal-title":"J Clin Oncol."},{"key":"2025033007272234900_CIT0007","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41408-020-00366-3","article-title":"International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)","volume":"10","author":"Mateos","year":"2020","journal-title":"Blood Cancer J."},{"key":"2025033007272234900_CIT0008","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1182\/blood-2022-168930","article-title":"Fixed duration therapy with daratumumab, carfilzomib, lenalidomide and dexamethasone for high-risk smoldering multiple myeloma: results of the ASCENT trial","volume":"140","author":"Kumar","year":"2022","journal-title":"Blood."},{"key":"2025033007272234900_CIT0009","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1182\/blood-2023-177954","article-title":"Immuno-PRISM: a randomized phase II plattform study of bispecific antibodies in high-risk smoldering myeloma","volume":"142","author":"Nadeem","year":"2023","journal-title":"Blood."},{"key":"2025033007272234900_CIT0010","article-title":"Evaluating early intervention in smoldering myeloma clinical trials: a systematic review","author":"Kakkilaya","year":"2024;219","journal-title":"The Oncologist"},{"key":"2025033007272234900_CIT0011","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1040-8428(00)00073-1","article-title":"The treatment of undifferentiated neuroendocrine tumors","volume":"37","author":"Mitry","year":"2001","journal-title":"Crit Rev Oncol Hematol."},{"key":"2025033007272234900_CIT0012","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/sj.cdd.4401881","article-title":"Cell cycle-dependent cytotoxic and cytostatic effects of bortezomib on colon carcinoma cells","volume":"13","author":"Coquelle","year":"2006","journal-title":"Cell Death Differ."},{"key":"2025033007272234900_CIT0013","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1038\/s41375-020-0747-7","article-title":"Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial","volume":"34","author":"Herling","year":"2020","journal-title":"Leukemia."},{"key":"2025033007272234900_CIT0014","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood.2021010845","article-title":"The CLL12 trial: ibrutinib vs placebo in treatment-na\u00efve, early-stage chronic lymphocytic leukemia","volume":"139","author":"Langerbeins","year":"2022","journal-title":"Blood."},{"key":"2025033007272234900_CIT0015","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1182\/bloodadvances.2018016998","article-title":"Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling","volume":"2","author":"Wu","year":"2018","journal-title":"Blood Adv."},{"key":"2025033007272234900_CIT0016","doi-asserted-by":"crossref","first-page":"e454","DOI":"10.1038\/bcj.2016.65","article-title":"Evolving changes in disease biomarkers and risk of early progression in smoldering multiple myeloma","volume":"6","author":"Ravi","year":"2016","journal-title":"Blood Cancer J."},{"key":"2025033007272234900_CIT0017","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/s41408-018-0077-4","article-title":"Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria","volume":"8","author":"Lakshman","year":"2018","journal-title":"Blood Cancer J."},{"key":"2025033007272234900_CIT0018","doi-asserted-by":"crossref","first-page":"102272","DOI":"10.1016\/j.eclinm.2023.102272","article-title":"Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey","volume":"65","author":"Mohyuddin","year":"2023","journal-title":"EClinicalMedicine."},{"key":"2025033007272234900_CIT0019","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/s41467-021-22140-0","article-title":"Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities","volume":"12","author":"Oben","year":"2021","journal-title":"Nat Commun."},{"key":"2025033007272234900_CIT0020","doi-asserted-by":"crossref","DOI":"10.1101\/2024.05.15.593193","article-title":"A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma","author":"Pilcher","year":"2024"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/3\/oyae266\/59640469\/oyae266.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/3\/oyae266\/59640469\/oyae266.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T20:15:00Z","timestamp":1743452100000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyae266\/7815776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,10]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyae266","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,10,8]]},"article-number":"oyae266"}}